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KRAS mutations are highly prevalent in non-small cell lung cancer (NSCLC), and tumors
harboring these mutations tend to be aggressive and resistant to chemotherapy.We used
next-generation sequencing technology to identify pathways that are speciﬁcally altered in
lung tumors harboring a KRAS mutation. Paired-end RNA-sequencing of 15 primary lung
adenocarcinoma tumors (8 harboring mutant KRAS and 7 with wild-type KRAS) were per-
formed. Sequences were mapped to the human genome, and genomic features, including
differentially expressed genes, alternate splicing isoforms and single nucleotide variants,
were determined for tumors with and without KRAS mutation using a variety of computa-
tional methods. Network analysis was carried out on genes showing differential expression
(374 genes), alternate splicing (259 genes), and SNV-related changes (65 genes) in NSCLC
tumors harboring a KRAS mutation. Genes exhibiting two or more connections from the
lung adenocarcinoma network were used to carry out integrated pathway analysis. The
most signiﬁcant signaling pathways identiﬁed through this analysiswere theNFκB, ERK1/2,
and AKT pathways. A 27 gene mutant KRAS-speciﬁc sub network was extracted based
on gene–gene connections from the integrated network, and interrogated for druggable
targets. Our results conﬁrm previous evidence that mutant KRAS tumors exhibit activated
NFκB, ERK1/2, andAKT pathways andmay be preferentially sensitive to target therapeutics
toward these pathways. In addition, our analysis indicates novel, previously unappreciated
links between mutant KRAS and theTNFR and PPARγ signaling pathways, suggesting that
targeted PPARγ antagonists and TNFR inhibitors may be useful therapeutic strategies for
treatment of mutant KRAS lung tumors. Our study is the ﬁrst to integrate genomic features
from RNA-Seq data from NSCLC and to deﬁne a ﬁrst draft genomic landscape model that
is unique to tumors with oncogenic KRAS mutations.
Keywords: transcriptome sequencing, RNA-Seq, KRAS mutation, NSCLC, bioinformatics, network analysis,
data integration and computational methods
INTRODUCTION
The most common form of lung cancer is histologically deﬁned
as non-small cell lung cancer (NSCLC). Activating mutations in
the KRAS oncogene are often found in NSCLC patients with
smoking history (Eberhard et al., 2005; Pao et al., 2005b). The
KRAS oncogeneharbors activatingmutations, especially in codons
12 or 13; and such mutations are prevalent in pancreatic can-
cer (Almoguera et al., 1988), leukemia, colorectal carcinomas
(Andreyev et al., 1997), and about 20–30% of lung adenocarcino-
mas (Riely et al., 2009). Another prevalent oncogene in NSCLC
is the epidermal growth factor receptor (EGFR). EGFR kinase
domain mutations have been established as valid predictors of
therapeutic response to EGFR-targeted therapeutics such as the
small molecule EGFR inhibitors geﬁtinib, erlotinib, and lapatinib
and theEGFRantibody cetuximab. In contrast, the therapeutic sig-
niﬁcance of KRAS mutations in NSCLC remains unclear and no
clinically usefulKRAS inhibitors have been developed formanage-
ment of NSCLC patients (Riely et al., 2009). In NSCLC, activating
KRAS mutations are predominant and are mutually exclusive of
mutations in EGFR. Studies indicate that lung adenocarcinoma
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patients with KRAS mutations are associated with resistance to
EGFR inhibitors (Eberhard et al., 2005; Pao et al., 2005a; Mas-
sarelli et al., 2007). The mechanisms that underlie such resis-
tance are largely unknown, and there is a very pressing need to
identify and exploit new molecular targets for management of
patients with NSCLC tumors with KRAS mutations. Since onco-
genic KRAS has proved to be difﬁcult to target directly (Vojtek
and Der, 1998; Shields et al., 2000), an alternative strategy is
to identify signaling pathways that are activated downstream of
mutant KRAS and to develop key nodal components of these
pathways as therapeutic targets using next-generation sequencing
technology.
There is very little information on differential gene expression
in NSCLC tumors with and without KRAS mutation. Interro-
gation of oncomine and gene expression omnibus (GEO) data-
bases revealed few studies that have focused speciﬁcally on the
relationship of KRAS mutation with gene expression in lung
adenocarcinomas patients (Beer et al., 2002) or cell lines (Bild
et al., 2006; Singh et al., 2009). Furthermore, most of these
studies are based on Affymetrix Hu6800 oligonucleotide arrays
and analytical technology that is, by modern standards, relatively
immature to study gene expression proﬁles. Thorough analy-
sis of microarrays led us to conclude that there is little reli-
able data on differential patterns of gene expression in NSCLC
tumors with and without KRAS mutations, and virtually no
genomic studies of somatic mutations, splice variants, or fusion
gene products that are speciﬁcally associated with such tumors
is available. Deep sequencing of transcriptome (RNA-Seq) pro-
vides a powerful tool to interrogate the whole transcriptional
landscape. Therefore, we combined RNA-Seq with sophisticated
methods and new analytical pipelines developed by our group
to analyze RNA-Seq data, to revisit the challenge of identifying
genomic features that deﬁne differences in the genomic land-
scape of KRAS-mutated and KRAS-wild-type primary NSCLC
tumors.
In the present study, we identiﬁed genomic features such as dif-
ferential gene expression, alternate splice variants, and expressed
polymorphisms that are signiﬁcantly involved in NSCLC tumors
harboring KRAS-mutated tumors when compared to KRAS-
wild-type tumors (Figure 1). These genomic features were then
used to develop a human NSCLC interactome network. Our
analysis represents the ﬁrst reported effort to integrate gene
expression, alternatively splicing, and nucleotide sequence vari-
ation data into a model that deﬁne a genomic landscape unique
to NSCLC tumors harboring oncogenic KRAS mutations. Our
results, in addition to validating previous studies on the role of
RAF, ERK1/2, AKT, and NFκB in mutant KRAS NSCLC, also
reveal novel links to other druggable target pathways including
TNFR and PPARγ. Our results indicate that this approach will
lead to novel insights into the biology of mutant KRAS tumors
and identify novel druggable pathways to treat KRAS-mutant
tumors.
MATERIALS AND METHODS
DATA SHARING
The sequence data used in this manuscript have been deposited in
GEO (GSE34914).
FIGURE 1 | Our data analysis approach. High-level representation of our
approach to analyze RNA-Seq data in human lung adenocarcinomas with
and without KRAS mutation.
SAMPLES
We performed RNA-sequencing of 15 lung adenocarcinomas, 8
with KRAS mutation and 7 without KRAS mutation. All tumors
were grade I or II and were obtained from surgical resection.
Tumors were macrodissected to remove normal tissue prior to
freezing, and all samples were histologically evaluated and deter-
mined to be>70% tumor tissue. TheKRAS mutational status was
determinedbypolymerase chain reaction (PCR) ampliﬁcation and
conﬁrmed by Sanger sequencing of exon 1 of KRAS. These studies
were carried out under Mayo Clinic IRB protocol 08-005844.
RNA PREPARATION AND SEQUENCING
Total RNA was prepared from 15 fresh frozen lung adenocarcino-
mas. All RINs were>7.0, as determined using the Agilent Bioana-
lyzer. The cDNA librarieswere prepared frompolyA enrichedRNA
using Illumina protocols. cDNA fragments of 300–400 bp were
selected,andnon-directional 50nucleotide paired-end sequencing
was performed as described previously (Sun et al., 2011). Sequenc-
ingwas carried out atMayoClinicAdvancedGenomic Technology
Center at Rochester, MN, USA using the Illumina Genome Ana-
lyzer II (GA II). One tumor sample without KRAS mutation was
run twice for QC evaluation. The FASTQ read ﬁles for the 16 sam-
ples were used for further data analysis. Data for gene counts was
obtained using our Mayo Clinic pipeline and Burrows–Wheeler
Alignment (BWA) alignment. Twenty toﬁfty-twomillion tagswere
obtained from sequencing. The percent of reads mapped for 16
samples varied from 71 to 84.2%. Table 1 consists of details from
sample statistics for paired-end runs; the table contains counts
combined for each sample from both reads.
DATABASES AND SOFTWARE USED FOR ANALYSES
Gene expression and alternate splicing data analyses were carried
out by downloading database tables from the UCSC table browser
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in reference to human genome build GRCh37, which corresponds
to UCSC hg19 assembly (Fujita et al., 2011). 1000g2010nov data
was obtained from the 1000 Genomes Project PHASE, 2010
November release1 and dbSNP version 1322 was used for sin-
gle nucleotide variation (SNV) analysis. SIFT database provided
by http://sift-dna.org/was used to predict whether an SNV coding
an amino acid substitution will affect protein function. ANNO-
VAR was used to functionally annotate genetic variants (Wang
et al., 2010). TopHat (Trapnell et al., 2010) and BWA tools (Li and
Durbin, 2009) were used to align RNA-Seq reads. Most of the sta-
tistical analyses were conducted using R: a language and environ-
ment for statistical computing3. Quantiﬁcation of splicing from
paired-end reads was performed using an R package – CASPER to
infer gene alternative splicing patterns from paired-end sequenc-
ing data (Rossell, 2010). Partek software tools were used for plot
generation and data mining purposes. A Microsoft SQL server
database was used to store and query data for analysis. A series of
computational programswaswritten using Perl scripting language
to access and ﬁlter data from the Microsoft SQL database.
GENE EXPRESSION DATA ANALYSIS
The Illumina standard pipeline, GA II was employed for process-
ing of raw images, to make base calls and to generate FASTQ
sequence reads from paired-end RNA-sequencing data. The exon–
exon boundary database was generated using exon and gene
deﬁnitions obtained from UCSC refFlat table for hg19 assembly.
Uni-directional combinations of exon junction database for the
sequencing length (50 bases) were generated using exon bound-
aries deﬁned by the refFlat ﬁle from UCSC Table Browser. FASTQ
sequence reads were aligned to the human reference genome
(hg19) and to our in-house exon junction database using BWA.
BWA is a fast and accurate short read aligner. A maximum of
two mismatches were allowed for ﬁrst 32 bases in each align-
ment, and reads that had more than two mismatches or were
mapped to multiple genomic locations (alignment score less than
3) were discarded. The aligned sequence tags were summarized
and annotated using SnowShoes, an in-house RNA-Seq pipeline
(manuscript in preparation). The read counts for genes are gener-
ated for further downstreamanalyses.Anon-mutantKRAS sample
that was run twice had high correlation; hence we took the aver-
age read count for each gene for that sample. Raw read counts
for a total of 22,316 genes were obtained for gene expression
analysis. Genes (15,092) that had a median read count >24 (16
reads) in at least one of the KRAS groups were used for further
analysis. Individual read count data were normalized using mode,
as follows: read count/sample read count mode ∗sm, where sm
is the smallest mode across all the samples. Since the length of
the transcript is assumed to be constant when comparing two
sample cohorts, no normalization for the length of genes was
performed for differential expression analysis.ANOVA implemen-
tation of Partek Genomics Software was used for differential gene
expression analysis after normalizing RNA-Seq gene count data.
Microarray data used in this studywere normalizedwith gc-robust
1http://www.1000genomes.org
2http://www.ncbi.nlm.nih.gov/projects/SNP/index.html
3 http://www.r-project.org
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multi-array average (gcRMA) algorithm, using Partek Genomics
(Partek Inc., St Louis, MO, USA). Normalized microarray data
were analyzed using ANOVA implementation of Partek Genomic
Software for differential gene expression analysis.
ALTERNATE SPLICING DATA ANALYSIS
TopHat is a fast splice junction mapping software that uses
short read aligner – Bowtie to align RNA-Seq reads (Langmead
et al., 2009; Trapnell et al., 2010). TopHat outputs alignments in
sequence alignment/map (SAM) format. Samtools (Li et al., 2009)
were used to convert ﬁles to binary alignment/map (BAM) for-
mat. BAM ﬁles were loaded into Bioconductor, and the CASPER
package4 was used to quantify known splicing variants. Brieﬂy,
CASPER obtains the list of known splicing variants for each gene
from UCSC, and estimates their relative abundances by modeling
the reads as a mixture of multinomial distributions (Figure 2).
Maximum likelihood estimates of the relative abundances were
obtained via the EM algorithm (Dempster et al., 1977). Tran-
script expression data was obtained for each sample fromCASPER
analysis. Transcripts with no mapped reads were imputed with a
zero and all samples with transcript data were merged for splic-
ing analysis. Mann–Whitney–Wilcoxin test that does not assume
normality was performed to identify differential alternative splice
forms between the KRAS-mutant and KRAS-wild-type samples.
SNV DATA ANALYSIS
Novel SNVs and SNVs with different allelic frequencies in sam-
ples with and without KRAS mutations were also discovered
using transcriptome sequencing data. Analysis of SNVs from lung
adenocarcinomas has been performed using a variety of compu-
tational methods. Single reads from paired-end data for a sample
were aligned to exon–exon junction database and genome inde-
pendently with BWA default parameters (Figure 3). When a read
maps to junction and genome, the read that map to the junc-
tion gets priority and the read from genome mapping will be
ﬁltered. In addition to duplicate mapping reads, reads of low
quality (mapQ< 20) were also ﬁltered. From a paired-end RNA-
Seq, four ﬁles were obtained from junction and genomic BWA
4 https://sites.google.com/site/rosselldavid/software
FIGURE 2 | High-level approach of CASPER – a splicing analysis R
package. Flowchart of methods to quantify alternate splice forms from
RNA-Seq data.
alignments. As shown in Figure 3, a total of four BAM align-
ment ﬁles for each sample were used to create a pileup ﬁle. The
pile up ﬁle generated for each sample was used to predict single
nucleotide variants using SNVMix – a novel binomial mixture
model (Goya et al., 2010). The number of reference and alter-
nate base reads were obtained for every transcribed position in
the genome. SNVMix uses a probabilistic method based on a
binomial mixture model to infer genotypes. At each nucleotide
position in the data, there is one of three genotype states (Goya
et al., 2010) generated from sequence data: aa (homozygous for
the reference base), ab (heterozygous), and bb (homozygous for
the non-reference base). In order to minimize errors, only bases
with >Q20 base quality were considered in determining counts.
We also ﬁltered our SNV data against dbSNP version 132, the
1000 genomes project (see text footnote 1), the Illumina Body
Map 2.0 data from 16 normal tissues (data downloaded from
www.broadinstitute.org/igvdata/BodyMap/hg19/IlluminaHiSeq
2000_BodySites), and four normal lung epithelial cell samples
(Beane et al., 2011). Illumina body map data and normal lung
epithelial RNA-Seq was obtained in order to eliminate any pre-
viously described germ line variants. Illumina body map samples
and lung epithelial cell lines were processed for SNVs in the same
manner as our 16 lung adenocarcinoma samples. SNV data from
all samples were stored in a Microsoft SQL server 2005 database.
In-house programs were developed to ﬁlter and query data from
the database. ANNOVAR software was used to functionally anno-
tate andﬁlter genetic variants. Frequency comparisons of the SNVs
were performed using the Fishers exact test from Plink software5.
Additional ﬁltering of SNVswas performed using SNVdata gener-
ated from TopHat alignment in order to remove any false positive
SNVs arising due to alignment issues. A variety of ﬁlters were built
on forward and reverse directionality reads for SNVs, as described
in the text.
PATHWAY AND NETWORK ANALYSES
Ingenuity Pathway Analysis (IPA) software (Ingenuity® Systems6)
was used for pathway analysis. IPA constructs protein interac-
tions basedona regularly updated“IngenuityPathwaysKnowledge
Database.” The IPA knowledge database consists of millions of
relationships between proteins extracted from the biological liter-
ature. Each relationship betweenmolecules is createdusing the IPA
knowledge database. IPA was used to identify pathways based on
differential gene expression, alternate splicing and SNV gene sets.
Signiﬁcant pathways in IPA were identiﬁed using Fisher’s exact
test. The p-value indicates the likelihood of the input gene list or
proteins in a givenpathwayor networkbeing found together due to
random chance. Cytoscape, a popular open source bioinformatics
package, was used for complex network analysis and visualization
(Smoot et al., 2011). Integration of the genomic features (differ-
ential expression, alternative splice variants, and SNVs) was per-
formed using Cytoscape. Network analyzer, a Cytoscape plug-in,
was used to compute a comprehensive set of topological para-
meters for directed networks (Assenov et al., 2008). Number of
5 http://pngu.mgh.harvard.edu/∼purcell/plink
6 http://www.ingenuity.com
Frontiers in Oncology | Cancer Genetics February 2012 | Volume 2 | Article 12 | 4
Kalari et al. Next-generation sequencing of lung adenocarcinomas
FIGURE 3 | High-level approach to identify SNVs. Flowchart of methods to process RNA-Seq data to obtain SNVs using a variety of tools, databases, and
next-generation sequencing normal sample datasets.
edges,distributionof degree counts, andneighborhood connectiv-
ity scores were obtained for the integrated network using network
analyzer. Reactome was also used for network analysis. Reactome
consists of expert curated and peer-reviewed high quality data
to infer human functional interactions among genes7. Reactome
and human interactome8 databases were also used along with
Cytoscape to build networks.Only the genes that were expressed in
RNA-Seq data (median read count>16 in at least one of theKRAS
groups) were used as reference gene set during network analysis.
RT-PCR AND SANGER SEQUENCING VALIDATION
Genomic DNAwas extracted fromNSCLC tumors using standard
protocols. The seven SNVs corresponding to genes (KRAS,GSTZ1,
ECT2, GLS, WDTC1, SRSF3, and RBM23) were evaluated using
Sanger sequencing. Primer pairs for these SNVs were designed
with Primer3 version 4.0 software, and were used to amplify all
variants by PCR. PCR products were puriﬁed from unincorpo-
rated nucleotides using a Millipore PCR puriﬁcation plate. A total
volume of 10μl, containing 80 ng of the clean product and 1.6 pM
of one of the primers (forward or reverse), was used for sequenc-
ing. Electropherograms were analyzed with SeqScape v2.5 (ABI,
Applied Biosystems, Foster City, CA, USA).
Quantitative real time PCR (qPCR) was used to verify alterna-
tive splicing of selected candidate transcripts. Total 1μg of RNA
was isolated and converted to cDNA using Applied Biosystem’s
High Capacity cDNA RT kit (Part # 4368813). Note that the
protocol for cDNA library construction for qPCR was different
from that used for RNA-Seq analysis, so as to minimize potential
7 http://www.reactome.org
8 http://cytoscape.wodaklab.org/wiki/Data_Sets
artifacts that might arise during cDNA conversion. Probes and
primers corresponding to known exon/exon junctions were pur-
chased fromLife Tech (Applied Biosystems) and qPCRwas carried
out using an AB 7900HT analyzer.
RESULTS
DIFFERENTIAL GENE EXPRESSION ANALYSIS
Read counts were obtained for 22,316 genes from 15 lung ade-
nocarcinoma samples with and without KRAS mutation. The
read count data were normalized using mode normalization and
log2 transformation as described in the Section “Materials and
Methods.” Genes with a median read count <16 in lung adeon-
carcinoma samples with and without KRAS mutation were elim-
inated from further analysis. The remaining 15,092 transcripts
were analyzed using ANOVA to identify 374 transcripts that were
differentially expressed genes in KRAS mutation samples versus
KRAS-wild-type sampleswith p-value<0.05 and twofold-changes
in gene counts. The association between the KRAS genotype and
the top six differentially expressed genes is shown in Figure 4A.
Hierarchical clustering of the 374 differentially expressed genes is
shown in Figure 4B, in which total gene counts were standardized
by the mean value among the samples.
Ingenuity pathway analysis was used to determine biological
relationships among the 374 differentially expressed genes. The
top ﬁve networks, based on Fisher’s exact test, were associated
with immunological disease, cell signaling, cell death, nervous
systemdevelopment, and function and cellular development path-
ways. The key nodes of the ﬁve networks are NFκB, ERK1/2,
AKT, MAPK, PI3K complex, IL12, and JNK. The top four net-
works (gene–gene relationships) from IPA analysis are shown in
Figures 5A–D. IPA also determines the number of subgroups
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FIGURE 4 | Results from differential gene expression analysis. (A)Top six signiﬁcantly differentially expressed genes between KRAS-mutant genotype (GT)
and KRAS-wild-type genotype (GG). (B) Hierarchical clustering of 374 genes that are differentially expressed with at least twofold-change and p-value <0.05.
of genes that are associated with a known or canonical path-
way. The top 3 canonical pathways from the 374 gene list are
cell cycle regulation by B-cell translocation gene (BTG) family
proteins, glioblastoma multiforme signaling, and Wnt/β-catenin
signaling.
ALTERNATIVE SPLICING ANALYSIS
We used CASPER, an R package, to obtain the expression of iso-
forms for all the refseq genes or transcripts. The UCSC hg19
assembly consists of 31,599 known transcripts. Genes with only
one known isoform were removed from the analysis (13,633 tran-
scripts). CASPER estimates relative expression levels, i.e., propor-
tion of transcripts for a given gene originating from each variant.
Transcript expression values from individual samples were orga-
nized into a single ﬁle and transcriptswithno readswere set to zero.
Data from CASPER ﬁles contained 17,966 transcripts for further
analysis. There were 314 transcripts corresponding to 259 genes
with a p-value<0.05 and minimum twofold-change in median of
multiple ratios between KRAS-mutant and wild-type samples. An
example of output from CASPER package is shown in Figure 6.
The estimated abundance of alternatively spliced NM_00268 and
NM_053024 transcripts is 66.79 and 33.21 for the proﬁling two
gene PFN2 in KRAS mutated samples (Figure 6A), whereas the
abundance ratios for NM_00268 and NM_053024 transcripts are
estimated as 82.28 and 17.72% respectively for KRAS-wild-type
samples (Figure 6C). Figures 6B,D show the reads for PFN2
transcripts for the same KRAS mutated and wild-type lung ade-
nocarcinoma samples. We also analyzed data using junction data
obtained from TopHat to identify isoforms. Our in silico analy-
sis of junction data for PFN2 gene from TopHat is similar to
CASPER data and indicates that the short isoform (NM_002628)
is abundantly expressed in KRAS-mutant samples compared to
KRAS WT group.
For pathway analysis using IPA, we have used the 259 genes
corresponding to 314 transcripts. The top ﬁve networks from IPA
analysis were associated with cellular growth and proliferation,
cell-to-cell signaling and interaction, nervous systemdevelopment
and function, molecular transport, and infection mechanisms.
Similar to the pathway analysis of differentially expressed genes,
the key nodes in the top ﬁve networks were NFκB, ERK1/2, SNCA,
AKT, PKC, MAPK, and Insulin.
SNV ANALYSIS
The SNVs that are ±5 kb from a refseq gene were obtained and
ﬁltered based on several criteria as described in Section “Materials
andMethods.”From the SNVMix output, genotypes ranging from
60 to 120million per sample were investigated to call an SNV.
Nucleotide sequence at every genomic coordinate was evalu-
ated when we had sufﬁcient depth of sequence.We evaluated each
nucleotide position for read depth, and for reads supporting the
reference and alternate alleles for an SNV.An SNVwas called when
the genotype of one or more samples deviated from the reference
genome genotype. In the current analysis, a SNV was not investi-
gated if the genotype consists of multiple alleles, if there was no
variation in genotype, or if the variation is present in less than two
samples.We also eliminated SNVs from further analysis if the read
depthwas<3.After the application of the ﬁlters described above, a
ﬁnal set of 73,717 unique single nucleotide variants remained for
further investigation. Since we have considered the regions that
are close to a gene for SNV investigation, the majority of the SNVs
are present in exonic (34,411) and 3′ UTR (25,736) regions. Of
the 34,411 exonic SNVs, there are 11,949 synonymous SNVs that
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FIGURE 5 | Network analysis. (A–D)Top networks identiﬁed with IPA software for the 374 genes that are differentially expressed between KRAS-mutant and
wild-type lung adenocarcinoma samples. The pink or red color nodes in networks indicate a gene that is up regulated in KRAS-mutant compared to the
KRAS-wild-type, green color indicates the genes that are down regulated in KRAS-mutant samples compared to the KRAS-wild-type samples.
do not change an amino acid. Hence, we ignored these SNVs and
estimated alternate allele frequencies from genotype data obtained
fromSNVMix software between the lung adenocarcinomas groups
in 23,987 non-synonymous, exonic SNVs. For additional investi-
gation of SNVs, we also obtained the 1000 genome and dbSNP132
data for all the 23,987 SNVs which include non-synonymous, stop
gain, and stop loss mutations.
Fisher’s exact test, called from PLINK software, was used to cal-
culate differences in alternate allele frequencies. Eighty-four SNVs
corresponding to 74 genes had a p-value <0.05 between tumor
samples with and without KRAS mutation. Table 2 shows details
of 13 SNVs with a p-value <0.01. Table 2 consists of 18 columns
with a variety of information for 13 SNVs.
Table 2 consists of details of SNV (chr, chromosome; Position,
chromosome location; Gene, gene corresponding to SNV; Ref, ref-
erence allele;Alt, alternate allele; KRASMut, frequency of alternate
allele observed in KRAS mutation group; KRAS WT, frequency
of alternate allele observed in group without KRAS mutation;
MAF,minor allele frequency; P, Fishers exact p-value; 1KGenome,
frequency of alternate allele observed in 1000 genome samples;
dbSNP132, dbSNP ID based on chromosome location if it exists;
SIFT, SIFT score that predicts amino acid changes that may be
affected by protein function; MAF Body Map, frequency of alter-
nate allele in Illumina body map 16 tissues that are sequenced
and analyzed similarly for SNVs; Illumina Lung, genotype of Illu-
mina lung sample from body map data and lung epithelial geno-
types for NormNonSmoker – normal non-smoker; NormSmoker,
normal smoker; SmokerNon-Cancer, smoker non-cancer; and
SmokerLungCancer, smoker lung cancer samples respectively). “?”
represents data not available in Table 2.
As shown in Table 2, the top signiﬁcant SNV located on chro-
mosome 12 corresponded to the KRAS gene. Thus, our SNV
analysis conﬁrms our in silico validation of sample classiﬁcation
based on KRAS mutational status. In addition to KRAS muta-
tion there are an additional 79 SNVs that are present in the 1000
genome dataset with a minor allele frequency (maf) ranging from
0.95 to 0.02 (medianmaf = 0.35) and fourmore SNVs that are not
present in the 1000 genome or dbSNP132 datasets, but which are
differentially observed in theKRAS-mutant andwild-type samples
with Fisher’s exact p-value<0.05.
To test if any of the four SNVs, corresponding to WDTC1
(chr1:27630115),GLS (chr2:191819311), SRSF3 (chr6:36564670),
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FIGURE 6 | Output of CASPER from splicing analysis. (A) CASPER
output for alternate splice forms in KRAS-mutant sample. The data
indicates that NM_002628 transcript is highly abundant compared to
NM_053024 transcript of PFN2 gene. (B) Observed reads for PFN2 gene.
Black lines in upper section of the plot indicates long reads and gray lines
indicate short reads typically spanning a single exon. The gray line on
bottom half of plot indicates coverage at each position. (C) CASPER output
for KRASWT sample. NM_053024 transcript is predominantly expressed
compared to other transcript. (D) Is similar to (B) but it corresponds to
KRASWT sample in (C).
and RBM23 (chr14:23370943) are novel, we performed TopHat
alignment and individually examined the data in nucleotide
sequence pileup ﬁles created from TopHat bam ﬁles. SNVs cor-
responding to RBM23 and GLS are located at exonic splicing
junction. Hence the alignments for these two variants were also
examined carefully in integrative genomic browser (IGV). We
found that the reads supporting the alternate allele for these two
variants were present at the 5′ ends of the sequence reads, and
therefore likely to represent sequence and/or alignment errors.
Hence we dropped these two SNVs from our analysis. The SNV
corresponding to WDTC1 was not called as a variant during
TopHat alignment. There were no reads supporting the alternate
allele,hencewediscarded that as a novel variant. Finally,we investi-
gated the variant corresponding to SRSF3 from TopHat alignment
and pileup data. This variant had an average read depth of 184;
however, we found there is a strand bias of reads for the alternate
allele. Thus, reads supporting the alternate allele C in the forward
strand were 21, compared to 565 reads from the negative strand,
such that this SNV was also eliminated on this basis.
We then ﬁltered the remaining differentially detected SNVs to
eliminate those that are at a splice junction, have alternate alleles
that are exclusively found at the 5′ end of the reads, or have strand
bias for alternate reads. These rules plus a limit for maximum read
depth to call an SNV and genotype conﬁdently using SNVMix
were applied to remove false positives. This led us to 72 SNVs
corresponding to 65 genes that have different allelic frequencies
between the tumors with and without KRAS mutation.
An IPA analysis was carried out on the 65 genes corresponding
to SNVs that have a preferential alternate allele present in samples
with or without KRAS mutation. The top ﬁve networks were asso-
ciated with tumor morphology, cellular growth and proliferation,
cell death, cellular function and maintenance of cancer, neurolog-
ical disease, cellular development, cell cycle, and cell morphology.
The most signiﬁcant disease associated with these SNVs was can-
cer and the key nodes in the top ﬁve networks were NFκB, ERK1/2,
AKT, TNF, PI3K, ESR1, beta estradiol, and TGFB1.
INTEGRATION ANALYSIS
Genes from differential expression (374 genes), alternate splicing
(259 genes), and SNV (65 genes) analyses were used for integration
analyses. Genes existing in multiple features were removed such
that the ﬁnal gene set for integration analysis consisted of 659
unique genes. Chromosomal mapping of these 659 genes iden-
tiﬁed several lung adenocarcinoma-speciﬁc clusters (Figure 7).
Individual evaluation of chromosomes suggest that there may be
clusters of genes on chromosomes 1, 3, 6, and 11 that are associated
with KRAS lung adenocarcinomas (Figure 7).
NFκB, ERK1/2, and AKT canonical pathways were observed in
all three independent feature analyses and also in the integrated
analysis of 659 genes. The NFκB pathway has previously been
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shown to be essential for the development of tumors with KRAS
mutation in a mouse model of lung adenocarcinoma (Meylan
et al., 2009). Previous studies have also shown the involvement
of AKT (Okudela et al., 2004) and ERK1/2 canonical pathways
(Blasco et al., 2011) in mutant KRAS lung adenocarcinomas. In
independent feature analyses, the MAPK pathway is targeted by
both differential gene expression and alternate splicing but not
with SNVs. Similarly, PI3K has been shown to target through
differential gene expression and SNV features but not by alter-
native splicing. These data indicate pathways involved in mutant
KRAS tumors are targetedbymultiple geneticmechanisms in these
tumors.
RT-PCR GENE VALIDATION
We randomly selected 6/15 samples for qPCR validation of four
differentially expressed genes identiﬁed in our RNA-Seq analysis.
Signiﬁcant correlations were observed ranging from 0.69 to 0.84,
when qRT-PCR results were compared with RNA-seq expression
data (data not shown).We also randomly selected two small genes
with multiple splice variants for functional validation.
Two genes, one with two splice variants and another with
more than two splice variants were used for functional valida-
tion of our splicing analysis. As shown in Figure 8, qPCR data
of samples agree with CASPER analysis for PFN2. KRAS-mutant
samples preferentially express the NM_002628 variant of PFN2
when compared to the NM_053024 variants (Figure 8). The two
most signiﬁcant SNVs (KRAS and GSTZ1) showing differences
in frequency in KRAS-mutant versus wild-type tumors were vali-
dated using Sanger sequencing of genomic DNA. The presence of
the reference and alternate allele (A) is shown in IGV Browser
(Figure 8B). Sanger sequencing validation of the SNV is also
shown in Figure 8C.
NETWORK ANALYSIS
A 659 gene set obtained from our integration analysis was used
to build lung adenocarcinoma networks. Reactome and protein–
protein interactome databases were used to build networks using
Cytoscape. Linker genes (genes not present in our list but known to
interact with genes in our list based on the published literature or
protein-protein interaction databases) were also included to con-
struct networks using Cytoscape. Thus, our lung adenocarcinoma
network consists of linker genes and the set of genes obtained from
different genomic features of RNA sequencing analyses. The func-
tionality and directionality of connections between the nodes are
also indicated in Figure 9. Topological parameters of the directed
network were obtained using network analyzer. Table 3 consists
of the top 50 genes from this analysis along with edge count,
degree, and neighborhood connectivity parameters. As shown in
the Table 3,MAPK14 is a linker gene consisting of 63 edge counts,
12 outgoing edges, and 51 in degree edges, with a high neighbor-
hood connectivity score of 23.71. Most of top genes from network
analysis are linker genes, due to the fact that most of these genes
are well established regulators of our candidate genes derived from
different features of tumors. In summary, the most signiﬁcant
connected genes (hubs) from our analyses are MAPK14 (linker
gene),andCCND1 fromdifferential gene expression,LAMA4 from
SNV, and RPS27A from alternate splicing analysis.
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FIGURE 7 | Genomic view diagram. Chromosomal view of all the genes
obtained from multi-feature analysis of lung adenocarcinomas with and
without KRAS mutation. Chromosomes 1, 3, 6, and 11 consists of abundant
gene clusters associated with KRAS mutation. Arrow in the diagram
represents a gene obtained from genomic feature analysis. Arrows identify
the loci of genes obtained from genomic feature analysis. Larger arrows are
shown when the genes are far apart, but when the gene locations are
adjacent they are represented as smaller arrows.
To understand the connections between these genes in terms
of known druggable targets and pathways we used IPA soft-
ware. We obtained 387 genes that had at least two or more
edges from the lung adenocarcinoma network developed previ-
ously (Figure 9) and submitted these data to IPA analysis. The
387 gene set consisted of 171 linker genes and 216 genes that
were obtained from the multi-feature analysis of lung adeno-
carcinomas with and without KRAS mutation. In this way, we
identiﬁed canonical pathways that are prevalent in the 387 dataset.
Figure 10 represents the top canonical pathways identiﬁed in our
IPA analysis. The most signiﬁcant canonical pathway consisted
of 52/377 genes associated with molecular mechanisms of cancer
(Figure 10).
IDENTIFICATION OF KEY DRUGGABLE NODES FROM KRAS LUNG
ADENOCARCINOMA NETWORK
To speciﬁcally explore the connections of the lung adenocarci-
noma network with the KRAS gene, we obtained the upstream
and downstream connections that are speciﬁc to KRAS gene from
our 659 integrated multi-featured gene list. Figure 11 shows the
direct and indirect connections to KRAS. As shown in Figure 11,
there are 14 genes (LOC100506736, FBLN2,CCND1,AGRN,FBN1,
MYCN, NQO1, SCNN1, ST5, TNFRSF10B, PPARG, GAS1, PLCB3,
and IGF1) that are indirectly connected with KRAS from our 659
unique gene list obtained from three different genomic features.
To build and expand the KRAS sub-speciﬁc network, we also used
the grow feature in IPA to obtain direct gene-gene interactions
from the Ingenuity Knowledge Base. This analysis gave us an addi-
tional 12 genes (RAF1, RALGDS, RASSF1, ICMT, PTBP1, ELAVL1,
WT1, ESX1, Ras, FEZF, RASGRF2, and IGF2BP1) with direct con-
nections to KRAS. The IPA overlay feature for known drugs was
also used to determine if there are known FDA-approved drugs
or clinical drug candidates within the 27 gene KRAS sub network.
Three of the 27 genes are the target of known FDA-approved drugs
(RAF1, PPARG, and TNFRSF10B).
In the 27 geneKRAS subnetworkwe identiﬁed four knownbio-
markers for NSCLC (CCND1, KRAS, PPARG, and Ras). From the
Ingenuity knowledge base, it is known that human CCND1 pro-
tein and PPARG are useful biomarkers for measuring the efﬁcacy
of the PPARγ agonist pioglitazone hydrochloride in the treat-
ment of NSCLC. Similarly KRAS has been used as a biomarker
for cetuximab, pazopanib, carboplatin, and erlotinib treatment of
NSCLC. Interestingly, three therapeutic trials using PPARG ago-
nists in NSCLC are currently being conducted9. Given our current
analysis, it will be of interest to determine whether a correlation
between clinical beneﬁt andKRAS mutational status emerges from
these trials.
9 Clinicaltrials.gov
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FIGURE 8 |The qPCR validation and SNV validation results. (A) Validation
of CASPER estimations of relative abundances for PFN2 gene in two mutant
and wild-type samples using qPCR (B) Visualization of KRAS-mutant SNV
using IGV Browser. Coverage ﬁle and bam ﬁles are shown in the top part of
the IGV Browser output. The bottom part of the picture consists of Refseq
gene with nucleotides. Nucleotide position of chr12: 133384864 is displayed
in dotted columns of the ﬁgure, it shows that the reference allele at that
particular position is (C) and alternate allele present at that position is (A), so
the SNV at that position is (C/A) change. (C) Sanger sequencing data
conﬁrming the variation.
DISCUSSION
We have conducted an integration analysis of multiple genomic
features obtained from deep sequencing of NSCLC tumors with
and without KRAS mutation. To our knowledge, this report rep-
resents the ﬁrst attempt to leverage RNA-Seq data and a variety
of computational methods to obtain an integrated genomic land-
scape map that incorporates differential gene expression, alternate
splicing, and SNV data. This approach allowed us to comprehen-
sively mine lung cancer data to produce a genomic landscape of
NSCLC tumors. In our study, we took advantage of the genomic
features obtained from our NSCLC samples along with the 1000
Genome data (normal samples), dbSNP data, and the Illumina
body map data obtained from 16 normal tissues and the nor-
mal lung cell line data (Beane et al., 2011). Thus far there is
only one paper that published lung cancer data using RNA-Seq;
in that study, Beane and coauthors studied gene expression dif-
ferences determined by RNA-Seq to understand the impact of
tobacco smoke exposure in pooled samples fromnon-transformed
bronchial epithelial cells from smokers and non-smokers with and
without lung cancer. We used these data as “normal” controls
for our analyses. To date; there is very little genomic informa-
tion on differential gene expression, alternate splicing, and single
nucleotide polymorphisms in NSCLC tumors with and without
KRAS mutation. We searched oncomine, GEO databases for gene
expression studies and identiﬁed only two studies for which KRAS
status of the tumors was known. One study was published in 2002
and used Affymetrix Hu6800 gene expression chips for 96 lung
adenocarcinoma samples whose clinical parameters are known
(Beer et al., 2002). Collected prior to 2001, the Beer et al. cohort
contained 40 KRAS-mutants and 45 KRAS-wild-type samples,
the remainder being of unknown KRAS status. Microarray data
were reanalyzed to identify differentially expressed genes using
the approach described in Section “Materials and Methods.”Only
19 genes were differentially expressed at p-value <0.05 and fold
change>±2. More than likely these results reﬂect analytical deﬁ-
ciencies related to the state of the art in microarray development
that prevailed when these samples were analyzed. Another study
determined KRAS status in 38 samples for human mammary
epithelial cells and generated Affymetrix Human Genome U133
Plus2.0 (GSE3141) data (Bild et al., 2006).We reanalyzedGSE3141
data for which KRAS status was accurately published to identify
differentially expressed genes using the approach described pre-
viously. Thirty-eight samples (11 samples with KRAS mutation
and 27 samples without KRAS mutation) were used for analysis.
Four hundred thirty-ﬁve probe sets corresponding to 311 genes
were differentially expressed with a p-value<0.05 and with a fold
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Table 3 | List of top 50 nodes from lung adeonocarcinoma network.
Gene Edge count Indegree Outdegree Neighborhood connectivity Type
MAPK14 63 51 12 23.71 Linker
JUN 55 3 52 21.67 Linker
SP1 54 51 3 22.52 Linker
TP53 51 9 42 22.08 Linker
EP300 51 9 42 21.51 Linker
CREBBP 50 23 27 21.54 Linker
FYN 50 31 19 19.46 Linker
GRB2 50 34 16 22.26 Linker
CTNNB1 49 0 49 19.55 Linker
EGFR 46 16 30 25.76 Linker
NFKB1 45 28 17 23.56 Linker
RAC1 44 6 38 18.52 Linker
PIK3CA 43 0 43 27.12 Linker
MAPK3 43 5 38 26.30 Linker
AKT1 43 33 5 29.40 Linker
STAT3 41 29 12 26.49 Linker
CREB1 40 21 19 23.38 Linker
ITGB1 37 31 6 18.92 Linker
GNAI1 35 6 29 19.71 Linker
AR 35 6 29 28.97 Linker
RHOA 35 12 23 22.46 Linker
HDAC1 33 14 19 26.85 Linker
IL2 32 5 27 30.00 Linker
CBL 32 16 16 19.81 Linker
PRKACA 32 26 8 23.50 Linker
GNB1 30 10 20 20.23 Linker
EGR1 30 26 4 25.10 Linker
PRKCB 30 28 2 23.77 Linker
GNAO1 28 13 15 20.21 Linker
VEGFA 28 16 12 32.43 Linker
RXRA 26 1 25 24.35 Linker
RASA1 26 2 24 21.54 Linker
GNAQ 26 6 20 18.00 Linker
SP3 26 25 1 22.54 Linker
CALM1 25 19 6 18.12 Linker
ITGB3 25 20 5 22.00 Linker
HTT 25 21 4 24.96 Linker
LAMA4 24 16 8 21.33 SNV
CCND1 23 6 17 32.04 DE
ARRB2 23 6 17 20.17 Linker
TFAP2A 23 8 15 17.65 Linker
CASP3 23 9 14 21.13 Linker
ITGB2 23 18 5 18.17 Linker
RPS27A 22 12 10 21.14 AS
WT1 22 15 7.11 26.32 Linker
CRK 22 22 0 25.77 Linker
GNG2 21 1 20 15.95 Linker
ERBB2 21 3 18 28.19 Linker
GLI1 21 12 9 20.71 Linker
BRCA1 21 19 2 28.00 Linker
The statistics are based on the number of edge counts, neighborhood connectivity, in degree, out degree connection parameters obtained from network analyzer
application in Cytoscape.
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FIGURE 9 | Lung adenocarcinoma interaction network. In the diagram
white squares are linker genes. Dark pink are differentially expressed genes,
light blue are splicing variants, purple are genes that are differentially
expressed and alternately spliced. Green are genes corresponding to SNVs.
Blue dotted lines means indirect connections, blue solid lines indicate direct
evidence of connection between the genes.
change>±2. Only nine genes overlapped with our 345 differen-
tially expressed genes. This could be due to differences in the gene
expression patterns induced by oncogenic KRAS in breast versus
lung tissue.
Deep sequence analysis of totalmRNAmakes it possible to ana-
lyze tumor samples and to quantify differential gene expression,
alternative splicing, and SNV. There is always a concern that dif-
ferences in cellularity may affect the outcome of genomic analyses
of tumor tissue. We have attempted to minimize this potential
problem by selecting only tumor samples that were histologically
evaluated as >70% tumor tissue. In addition, there are several
bioinformatics challenges such as base calling, assembly, align-
ment, and after-alignment handling of huge amounts of data
from an RNA-Seq experiment. There are more than 300 soft-
ware tools for next-generation sequence alignment, assembly, base
calling, and post-alignment analysis10. We have used a combina-
tion of software tools for various analytical purposes. For each
genetic feature obtained in this study, we computationally vali-
dated our analysis using at least two or more combinations of
10 http://www.seqanswers.com
approaches. We have discussed our approach for each genetic fea-
ture in detail in Section “Materials and Methods.” Our results
demonstrate that transcriptome sequencing has the potential to
provide new insights in our understanding of the genomic con-
sequences of KRAS mutation in NSCLC patients by integrating
different genomic features.
Even though KRAS mutations are highly prevalent in cancers,
it has proven to be quite difﬁcult to exploit mutated KRAS as
a therapeutic target. Thus, a goal of our analysis was to identify
druggable targets that are genomic associated with the mutant
KRAS phenotype. Our analysis identiﬁed the RAF, ERK1/2, and
NFκB pathways as speciﬁcally associated with mutant KRAS. Each
of these pathways have previously been shown to be function-
ally linked to mutant KRAS tumorigenesis and represent bonaﬁde
drug targets for clinical treatment of KRAS tumors. Sorafenib
inhibits RAF1 and is currently being tested in NSCLC patients
in phase II trial11 (Blumenschein et al., 2009). In addition to
these previously known KRAS related drug targets, our analy-
sis revealed underappreciated links of mutant KRAS with the
11http://www.clinicaltrials.gov/ct2/show/NCT00870532
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FIGURE 10 | Most significant canonical pathway from this study.
Molecular mechanisms of cancer is the most signiﬁcant known
pathway obtained from multi-feature analysis of lung adenocarcinoma
network. In the diagram green symbols represent linker genes and red
or pink colors represent list of genes from lung adenocarcinoma
network.
FIGURE 11 | KRAS sub network.The network connections are obtained from our multi-feature gene list and Ingenuity knowledge base (IKB). Direct and
indirect connections to KRAS gene are obtained from multi-feature list and only direct connections are obtained from IKB. The bar chart close to the gene
indicates the log2 expression of the gene for each sample from RNA-sequencing data. Rx connection to a gene indicates FDA approved or clinical trial drugs.
Frontiers in Oncology | Cancer Genetics February 2012 | Volume 2 | Article 12 | 14
Kalari et al. Next-generation sequencing of lung adenocarcinomas
TNFR (Drosopoulos et al., 2005; Ji et al., 2006) and PPARγ
(Ignatenko et al., 2004) signaling pathways. Although our analy-
sis is the ﬁrst comprehensive transcriptome sequencing analysis
concerned with the mutant KRAS phenotype, it does not have
sufﬁcient power to detect all genes associated to NSCLC tumors
and KRAS. Thus, larger sample sizes will be desirable; and such
analyses are ongoing at this time. However, we submit that the
power of future studies is likely to be inherent in an integrated
analysis, of the sort that we have deﬁned here, which takes advan-
tage of all of the genomic features that can be identiﬁed using
RNA-Seq technology and leverages these technologies with new
analytical tools. The tools that are available to quantify and inte-
grate such features are currently in a state of rapid evolution
as many investigators struggle with the complex issues related
to building integrated systems models. The present model rep-
resents a ﬁrst draft, rather than a rigorously deﬁned genomic
landscape model; and we anticipate that ongoing work in our
laboratory and others will shortly lead to a better deﬁnition of
the salient genomic features that distinguish KRAS mutational
signaling events. However, our data demonstrate the utility of
these approaches to identify critical druggable targets that can be
exploited to manage the very signiﬁcant subset of NSCLC tumors
with KRAS mutations.
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